Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

MANHASSET, N.Y.–(BUSINESS WIRE)–The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research, its new President-Elect. Dr. Grande will serve a two-year term, followed by an additional two-year term as … [Read more…]

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

Advancing a broad portfolio designed to accelerate innovation and shape the future of treatment for weight loss, obesity-related conditions and metabolic diseases Clinical-stage pipeline includes oral and injectable incretin, non-incretin and combination therapies designed with best-in-class profiles to address multiple targets and meet the future needs of a rapidly evolving weight loss treatment landscape Founded … [Read more…]

PureTech Health: Notice of Results

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST … [Read more…]

The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report

‘First-of-its-kind’ study shows that adult immunisation programmes return up to 19 times their initial investment when the full spectrum of benefits is valued The findings highlight the opportunity to ease pressures on health systems by adopting a prevention-first mindset that includes adult immunisation programmes The report comes ahead of World Immunisation Week and reveals substantial … [Read more…]

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

 – Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women – – Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization – NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients … [Read more…]

VERDA Health Plan of Texas and IntegraNet Forge Strategic Partnership

HOUSTON–(BUSINESS WIRE)–Verda Health Plan is proud to announce a new, pivotal partnership with IntegraNet Health, Inc., a renowned Independent Practice Association (IPA). The alliance between the two Texas-based companies signifies a significant step forward in advancing the quality and accessibility of healthcare in underserved communities across the country. Verda Health Plan is a trailblazing Medicare … [Read more…]

VITAS Completes the Previously Announced Purchase of Assets of Covenant in Florida and Alabama

CINCINNATI–(BUSINESS WIRE)–VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE) announced the completion of the previously announced purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care (“Covenant”) for an aggregate purchase price of $85 million. The transaction is structured as an … [Read more…]

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a … [Read more…]

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure or … [Read more…]

BenevolentAI: Publication of the Revised Agenda for the 2024 AGM

LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 … [Read more…]